ClinicalTrials.gg
CompletedNCT01365052MUSTUpdated Jun 8, 2015Results posted

Safety Trial of Naproxen Sodium/ Diphenhydramine

A Phase 3 interventional study of Naproxen sodium 440 mg/DPH 50 mg (BAY98-7111) and Placebo in Pain, sponsored by Bayer. Completed at 19 sites in United States. Open to participants aged 12 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-06-08.

Sponsored by Bayer · Phase 3 and Interventional

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
326
Allocation
Randomized
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 25 studies testing naproxen in Pain — 1 open to participants now, 2 under way, none of them phase 3. Naproxen · Pain.

Enrollment
5th of 25
326 · median 100
Started
2011
with 2 others
Phase 3
5 of 25
none open now
Registered
5th of 25
by date
Lead sponsor
9 of 25
Bayer

Among the 25 studies testing naproxen in Pain, this one is the 5th largest by enrollment, is one of 3 that started in 2011, is one of 5 in phase 3, and was the 5th registered.

Pain

10,076 studies on the registry are indexed under Pain; 1,648 are open to participants now.

Browse Pain studies →

Open to participants now

1 of the 25 studies testing naproxen in Pain is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About naproxen

Naproxen: first FDA approval 1976 (NAPROSYN). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 928 Pain studies recruiting now, 384 (41%) set no upper age limit and 432 (47%) stop at 75 or younger; 145 take children under 18; 220 take healthy volunteers.

This study: 12 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies testing naproxen in Pain, or all of them as a file.
02

Study summary

The purpose of this trial is to see how safe the combination of naproxen sodium 440 mg and diphenhydramine hydrochloride (DPH) 50 mg (the investigational product) is compared to placebo (capsules containing no drug) when taken for 10 days.

03

Conditions studied

  • Pain

Browse trials for

Keywords

  • Maximum Use Safety Trial
04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy, ambulatory, male and female volunteers ages 12 and older
  • History of experiencing occasional sleeplessness accompanied by aches and pains at least two times, but not continually for more than 14 days per month, in at least 2 of the past 3 months
  • Female subjects of must be using a medically acceptable form of , e.g., oral or patch contraceptives, intrauterine device, Depo-Provera®, for at least 1 month prior to screening (3 months on oral contraceptives), or double-barrier and have a negative pregnancy test at Screening. Female subjects of nonchildbearing potential must be amenorrheic for at least 2 years or have had a hysterectomy and/or bilateral oophorectomy
  • Be willing and able to participate in all scheduled visits, treatment plan, tests and other trial procedures according to the protocol
  • Provide a personally signed and dated indicating that the subject has been informed of all pertinent aspects of the trial, (subjects \<18 years of age must sign a written assent and have parental or guardian consent).

Exclusion criteria

Exclusion Criteria:

  • History of to naproxen sodium, acetaminophen, or any NSAIDs (Nonsteroidal Antiinflammatory Drugs), diphenhydramine or any other antihistamines, and similar pharmacological agents or components of the product
  • Evidence or history of (in the judgment of the investigator) hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic diseases, or with the last 5 years
  • A history of a chronic or severe sleep problem which does not respond to OTC (Over-the-counter) medication and/or requires a prescription hypnotic or sedative
  • Currently experiencing chronic pain or on chronic NSAID therapy (defined as taking a daily [5 to 7 days per week] regimen of prescription or OTC NSAIDs)
  • Current or past history of gastrointestinal ulcers or bleeding or other bleeding disorders
  • Use of any OTC or prescription medications with which the administration of naproxen, acetaminophen, or any NSAIDs, diphenhydramine or any other antihistamines or sedatives, is
  • Chronic use of other products containing diphenhydramine, including topical products
  • Use of or blood thinning (anticoagulant) drugs (aspirin 81 mg is permitted if the dose has been taken for at least one month prior to screening)
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
326 participants (actual)

Study arms

  • Experimental
    Naproxen sodium 440 mg/DPH 50 mg (BAY98-7111)

    Drug: Naproxen sodium 440 mg/DPH 50 mg (BAY98-7111)

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • DrugNaproxen sodium 440 mg/DPH 50 mg (BAY98-7111)

    Drug page: NaproxenStudies of NaproxenNaproxen pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    2 capsules each containing naproxen sodium 220 mg /diphenhydramine hydrochloride (DPH) 25 mg are taken orally with a full glass of water approximately 30 minutes prior to bedtime for 10 consecutive days

  • DrugPlacebo

    2 placebo capsules are taken orally with a full glass of water 30 minutes prior to bedtime for 10 consecutive days

06

What researchers measure

Primary outcomes

  1. Percentage of Subjects With Any Adverse Event for Those Subjects Who Were Randomized and Took at Least One Dose of Investigational Product

    Please see further details in Adverse Events (AE) section

    Time frame: 10 days after randomization

  2. Percentage of Subjects With Any Serious Adverse Event for Those Subjects Who Were Randomized and Took at Least One Dose of Investigational Product

    Please see further details in AE section

    Time frame: 10 days after randomization

Other outcomes

  1. Percentage of Subjects Who Discontinued Due to an Adverse Event for Those Subjects Who Are Randomized and Take at Least One Dose of Investigational Product

    Time frame: 10 days after randomization

  2. Treatment Compliance - Number of Capsules Taken

    Time frame: 10 days after randomization

  3. Treatment Compliance - Duration of Exposure to Treatment in Days

    Time frame: 10 days after randomization

07

Results

Posted Jun 16, 2014

Participant flow

Participant flow — Overall Study
MilestoneNaproxen Sodium 440 mg/DPH 50 mg (BAY98-7111)Placebo
Started217109
Completed213105
Not completed44
Withdrew: Adverse event44

Outcome measures

Other pre-specifiedPercentage of Subjects Who Discontinued Due to an Adverse Event for Those Subjects Who Are Randomized and Take at Least One Dose of Investigational Product
Time frame:
10 days after randomization
Reported as:
Number · Percentage of participants
Percentage of Subjects Who Discontinued Due to an Adverse Event for Those Subjects Who Are Randomized and Take at Least One Dose of Investigational Product
Percentage of participantsNaproxen Sodium 440 mg/DPH 50 mg (BAY98-7111)Placebo
Percentage of Subjects Who Discontinued Due to an Adverse Event for Those Subjects Who Are Randomized and Take at Least One Dose of Investigational Product1.83.7
PrimaryPercentage of Subjects With Any Adverse Event for Those Subjects Who Were Randomized and Took at Least One Dose of Investigational Product

Please see further details in Adverse Events (AE) section

Time frame:
10 days after randomization
Reported as:
Number · Percentage of participants
Percentage of Subjects With Any Adverse Event for Those Subjects Who Were Randomized and Took at Least One Dose of Investigational Product
Percentage of participantsNaproxen Sodium 440 mg/DPH 50 mg (BAY98-7111)Placebo
Percentage of Subjects With Any Adverse Event for Those Subjects Who Were Randomized and Took at Least One Dose of Investigational Product39.645.0
PrimaryPercentage of Subjects With Any Serious Adverse Event for Those Subjects Who Were Randomized and Took at Least One Dose of Investigational Product

Please see further details in AE section

Time frame:
10 days after randomization
Reported as:
Number · Percentage of participants
Percentage of Subjects With Any Serious Adverse Event for Those Subjects Who Were Randomized and Took at Least One Dose of Investigational Product
Percentage of participantsNaproxen Sodium 440 mg/DPH 50 mg (BAY98-7111)Placebo
Percentage of Subjects With Any Serious Adverse Event for Those Subjects Who Were Randomized and Took at Least One Dose of Investigational Product00
Other pre-specifiedTreatment Compliance - Number of Capsules Taken
Time frame:
10 days after randomization
Reported as:
Mean · Capsules
Treatment Compliance - Number of Capsules Taken
CapsulesNaproxen Sodium 440 mg/DPH 50 mg (BAY98-7111)Placebo
Treatment Compliance - Number of Capsules Taken20.1 ± 1.7319.9 ± 2.98
Other pre-specifiedTreatment Compliance - Duration of Exposure to Treatment in Days
Time frame:
10 days after randomization
Reported as:
Mean · Days
Treatment Compliance - Duration of Exposure to Treatment in Days
DaysNaproxen Sodium 440 mg/DPH 50 mg (BAY98-7111)Placebo
Treatment Compliance - Duration of Exposure to Treatment in Days9.9 ± 0.769.8 ± 1.37

Adverse events

Collected over Treatment emergent adverse events (TEAEs) were collected from the date of the first dose of study drug in the treatment period for 12 days, or for 30 days after the last study drug administration if they were serious adverse events (SAEs).. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Naproxen Sodium 440 mg/DPH 50 mg (BAY98-7111)—0/217 (0%)86/217 (39.6%)
Placebo—0/109 (0%)49/109 (45%)
Most frequent other events
Showing 10 of 108
Most frequent other events
EventNaproxen Sodium 440 mg/DPH 50 mg (BAY98-7111)Placebo
HEADACHENervous system disorders23/21721/109
SOMNOLENCENervous system disorders10/2174/109
NAUSEAGastrointestinal disorders9/2171/109
DIZZINESSNervous system disorders9/2170/109
BACK PAINMusculoskeletal and connective tissue disorders8/2173/109
PAIN IN EXTREMITYMusculoskeletal and connective tissue disorders0/2174/109
DIARRHOEAGastrointestinal disorders7/2172/109
ABDOMINAL PAIN UPPERGastrointestinal disorders3/2173/109
OROPHARYNGEAL PAINRespiratory, thoracic and mediastinal disorders4/2173/109
ABDOMINAL DISCOMFORTGastrointestinal disorders5/2172/109

Baseline characteristics

Age, Continuous
Age, Continuous(years)Naproxen Sodium 440 mg/DPH 50 mg (BAY98-7111)PlaceboTotal
Mean46.9 ± 18.1447.1 ± 19.2647.0 ± 18.49
Age, Customized
Age, Customized(Participants)Naproxen Sodium 440 mg/DPH 50 mg (BAY98-7111)PlaceboTotal
<60 years152 ± 70.072 ± 66.1224
Greater than or equal to 60 years65 ± 30.037 ± 33.9102
>65 years46 ± 21.228 ± 25.774
Sex: Female, Male
Sex: Female, Male(Participants)Naproxen Sodium 440 mg/DPH 50 mg (BAY98-7111)PlaceboTotal
Female13365198
Male8444128
08

Study locations

19 sites
  • Chandler, Arizona 85224, United States
  • Mesa, Arizona 85203, United States
  • Peoria, Arizona 85381, United States
  • Anaheim, California 92801, United States
  • Rancho Cucamonga, California 91730, United States
  • Sacramento, California 95816, United States
  • Colorado Springs, Colorado 80922, United States
  • Kissimmee, Florida 34741, United States
  • Pembroke Pines, Florida 33028, United States
  • South Miami, Florida 33143, United States
  • Stockbridge, Georgia 30281, United States
  • Metairie, Louisiana 70006, United States
  • Elkridge, Maryland 21075, United States
  • Warwick, Rhode Island 02886, United States
  • Mt. Pleasant, South Carolina 29464, United States
  • Fort Worth, Texas 76135, United States
  • San Angelo, Texas 76904, United States
  • San Antonio, Texas 78231, United States
  • Salt Lake City, Utah 84106, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2011, a primary completion of Jul 2011 and a completion of Jul 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2014, 2 years 11 months after primary completion. A results delay was requested in May 2012.

How these figures are worked out, and which studies are left out of them.

Registered
May 17, 2011
First posted
Jun 3, 2011
Start
May 2011
Primary completionActual
Jul 2011
CompletionActual
Jul 2011
Results delay requested
May 30, 2012
Results first posted
Jun 16, 2014
Last update
Jun 8, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 8, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01365052
Lead sponsor
Bayer
Responsible party
Sponsor
First posted
Jun 3, 2011
Start date
May 2011
Primary completion
Jul 2011
Completion
Jul 2011
Results posted
Jun 16, 2014
Last update
Jun 8, 2015

Study contacts

Bayer Study Director
study director · Bayer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Naproxen

Start the discussion